Ms. Megan McCrae reports

ORGANIGRAM GLOBAL LAUNCHES HAPPLY, A NEW U.S. HEMP-DERIVED THC BRAND OFFERING TARGETED FORMULATIONS FOR THREE MOOD STATES; SOCIALIZE, RELAX, AND SLEEP

Organigram Global Inc. has launched happly, its third United States hemp-derived delta-9 brand, created specifically for the growing segment of consumers seeking "mindful recreation" with THC products. The launch of happly follows the company's entry into the growing U.S. hemp-derived THC market with its lineup of Collective Project sparkling juices and Fetch sodas earlier this year.

The hemp-derived THC category in the U.S. continues to experience growth driven by consumer access, convenience, discretion and wellness appeal. In addition, the U.S. continues to demonstrate forward-thinking leadership in the acceptance and advancement of hemp-derived cannabinoids.

Backed by extensive qualitative and quantitative consumer research, happly is thoughtfully designed from a brand and product perspective for individuals seeking moderation, control and predictability in their cannabis experiences. These consumers prioritize products with lower THC doses formulated specifically to address mood states including sleep, relaxation and socializing. According to Organigram's robust U.S. market segmentation study, the mindful recreation segment represents approximately 21 per cent of cannabinoid consumers, highlighting the strong demand for low-dose, functional products-driven in large part by a younger adult demographic with 63 per cent of this group being under the age of 34.

Introducing happly -- the right amount

"happly is more than just a new brand, it is about redefining how hemp-derived THC can be part of everyday life," said Megan McCrae, senior vice-president, corporate strategy and international growth, at Organigram. "It was designed by listening closely to consumers and creating a range of products they've been asking for with a focus on moderation, control, predictability and specific benefits. Most importantly, happly reflects a shift toward intentional hemp-derived THC use -- designed for everyday moments where consumers are seeking balance and being present rather than excess. Our targeted formulas make that possible, delivering the right effects and a consistent experience."

At launch, happly will debut with a lineup of three vegan, hemp-derived gummies, each thoughtfully crafted to address a specific consumer mood state: socializing, relaxation or sleep. Each gummy is infused with a precise blend of cannabinoids and carefully selected functional ingredients. For those seeking an energy boost during social moments, caffeine is incorporated; for relaxation, L-theanine; and for a restful sleep experience, chamomile extract is included. These formulations are designed to deliver targeted effects tailored to various occasions and preferences.

First U.S. use of FAST nanoemulsion technology

Setting happly apart from other products on the market, each gummy leverages proprietary FAST nanoemulsion technology. This innovative approach enables a more consistent and predictable onset and offset of effects, resembling the predictable effects of consuming alcohol. Notably, happly is Organigram's first U.S. brand to incorporate this technology, underscoring the company's commitment to innovation, quality and consumer satisfaction.

"We are incredibly excited to introduce our proprietary FAST nanoemulsion technology to the U.S. market through happly," said Borna Zlamalik, SVP of innovation and international R&D (research and development) at Organigram. "This milestone not only marks a significant step in commercializing advanced delivery systems for hemp-derived THC but also showcases the continued success of our Product Development Collaboration (PDC) with BAT in driving meaningful innovation. At Organigram, we remain steadfast in our commitment to placing innovation and consumer-centric products at the heart of our strategy, ensuring we deliver differentiated experiences and real value for our customers."

By harmoniously combining specific cannabinoids, functional ingredients and advanced delivery technology, happly enables consumers to receive "the right amount" for their desired experience -- whether that is promoting rest, encouraging relaxation or enhancing social interactions.

happly product portfolio

happly's inaugural innovative product lineup includes those shown in the attached table.

All 20-count products are thoughtfully packaged in slim, beautifully designed reusable tins. These tins are crafted to offer consumers a discreet, portable and functional option, making them suitable for a variety of occasions throughout the day. The design enables consumers to conveniently carry their gummies on the go, while also emphasizing both practicality and style.

Launch and availability

happly will initially launch via direct-to-consumer sales on-line, with shipping available to consumers in 23 states. DE, GA, IL, IN, KS, ME, MN, MO, NE, NV, NH, NJ, NM, NC, OH, OK, PA, SC, SD, TN, TX, WI and WY. Expansion into the retail channel is expected later this year.

About Organigram Global Inc.

Organigram is a Nasdaq Global Select Market and Toronto Stock Exchange-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Ltd., Organigram participates in the United States and Canadian cannabinoid beverage markets.

Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Shred'ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, Boxhot and Debunk. Organigram operates cultivation and processing facilities in Moncton, N.B., and Lac-Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates extract processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 (carbon dioxide) and hydrocarbon extraction capabilities, and is optimized for formulation refinement, postprocessing of minor cannabinoids, and preroll production. The facility in London is being optimized for labelling, packaging and national fulfilment.

We seek Safe Harbor.